1. Immunology/Inflammation Apoptosis Anti-infection
  2. COX Apoptosis Parasite
  3. Ibuprofen

Ibuprofen  (Synonyms: (±)-Ibuprofen)

Cat. No.: HY-78131 Purity: 99.97%
SDS COA Handling Instructions

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.

For research use only. We do not sell to patients.

Ibuprofen Chemical Structure

Ibuprofen Chemical Structure

CAS No. : 15687-27-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 15 publication(s) in Google Scholar

Other Forms of Ibuprofen:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC50 value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers[1][2][5][8].

IC50 & Target[1]

COX-1

13 μM (IC50)

COX-2

370 μM (IC50)

Cellular Effect
Cell Line Type Value Description References
Bel-7402 IC50
> 100 μM
Compound: Ibuprofen
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
Bel7402/5-FU IC50
> 100 μM
Compound: Ibuprofen
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
BGC-823 IC50
> 50 μM
Compound: Ibuprofen
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
Caco-2 IC50
> 50 μM
Compound: Ibuprofen
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
CHO IC50
200 μM
Compound: 1
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA
[PMID: 20503989]
CHO IC50
200 μM
Compound: 1
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA
[PMID: 21873070]
COS-7 IC50
> 1000 μM
Compound: Ibuprofen
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
HCT-116 IC50
448 μM
Compound: IB
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 20171760]
HCT-15 IC50
> 1000 μM
Compound: Ibuprofen
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
HT-29 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
HT-29 IC50
552 μM
Compound: IB
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
[PMID: 20171760]
Huh-7 IC50
37.2 μM
Compound: Ibu
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay
[PMID: 26810835]
K562 IC50
> 1000 μM
Compound: Ibuprofen
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
L02 IC50
> 100 μM
Compound: Ibuprofen
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay
[PMID: 28301815]
MCF7 IC50
> 50 μM
Compound: 6
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
MCF7 IC50
> 50 μM
Compound: Ibuprofen
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
MCF7 IC50
92.14 μM
Compound: Ibuprofen
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
MDA-MB-231 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
MDA-MB-231 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
MDA-MB-231 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
Neutrophil IC50
12.1 μM
Compound: Ibuprofen
Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay
Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay
[PMID: 18950230]
Neutrophil IC50
27.53 μM
Compound: ibuprofen
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins
[PMID: 20839880]
Neutrophil IC50
32.55 μM
Compound: ibuprofen
Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry
Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry
[PMID: 17822293]
PANC-1 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
PANC-1 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
PANC-1 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
PC-3 IC50
> 1000 μM
Compound: Ibuprofen
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
PC-3 IC50
> 50 μM
Compound: Ibuprofen
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
[PMID: 33799070]
RAW264.7 IC50
0.39 μM
Compound: Ibuprofen
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA
[PMID: 28408221]
RAW264.7 IC50
0.86 μM
Compound: Ibuprofen
Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay
Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay
[PMID: 24656662]
RAW264.7 IC50
14.4 μM
Compound: Ibuprofen
Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA
Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA
[PMID: 34890996]
RAW264.7 IC50
1483.87 μM
Compound: Ibuprofen
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA
[PMID: 28408221]
RAW264.7 IC50
2.1 μM
Compound: Ibuprofen
Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA
Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA
[PMID: 34890996]
RAW264.7 IC50
3309.84 μM
Compound: Ibuprofen
Cytotoxicity against mouse RAW264.7 cells by MTT assay
Cytotoxicity against mouse RAW264.7 cells by MTT assay
[PMID: 28408221]
RAW264.7 IC50
54.5 μM
Compound: Ibuprofen
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method
[PMID: 28561586]
SK-LU-1 IC50
90.61 μM
Compound: Ibuprofen
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
TERT-RPE1 IC50
> 40 μM
Compound: 6
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay
[PMID: 35468536]
U-251 IC50
> 1000 μM
Compound: Ibuprofen
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
[PMID: 32527536]
UACC-903 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay
[PMID: 26750401]
UACC-903 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 26750401]
UACC-903 IC50
> 50 μM
Compound: Ibu
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 26750401]
In Vitro

Ibuprofen (24 h) inhibits COX-1 and COX-2 activity with IC50 values of 13 μM and 370 μM[1].
Ibuprofen (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line)[2].
Ibuprofen (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell[2].
Ibuprofen (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells[3].
Ibuprofen (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: AGS cells
Concentration: 100-1000 μM
Incubation Time: 24 h, 48 h
Result: Inhibited AGS cell viability with IC50 values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).
In Vivo

Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer[5].
Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin induced peripheral neuropathy[6].
Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise[7].
Ibuprofen (35 mg/kg; p.o.; twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)[5]
Dosage: 300 mg/kg, daily for 14 days
Administration: Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)
Result: Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells.
Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.
Animal Model: Oxaliplatin‑induced peripheral neuropathy[6]
Dosage: 60 mg/kg, every second day for 15 days
Administration: Subcutaneous injection
Result: Lowered sensory nerve conduction velocity (SNCV).
Clinical Trial
Molecular Weight

206.28

Formula

C13H18O2

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC(C(C1=CC=C(CC(C)C)C=C1)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (484.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.8478 mL 24.2389 mL 48.4778 mL
5 mM 0.9696 mL 4.8478 mL 9.6956 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.97%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.8478 mL 24.2389 mL 48.4778 mL 121.1945 mL
5 mM 0.9696 mL 4.8478 mL 9.6956 mL 24.2389 mL
10 mM 0.4848 mL 2.4239 mL 4.8478 mL 12.1194 mL
15 mM 0.3232 mL 1.6159 mL 3.2319 mL 8.0796 mL
20 mM 0.2424 mL 1.2119 mL 2.4239 mL 6.0597 mL
25 mM 0.1939 mL 0.9696 mL 1.9391 mL 4.8478 mL
30 mM 0.1616 mL 0.8080 mL 1.6159 mL 4.0398 mL
40 mM 0.1212 mL 0.6060 mL 1.2119 mL 3.0299 mL
50 mM 0.0970 mL 0.4848 mL 0.9696 mL 2.4239 mL
60 mM 0.0808 mL 0.4040 mL 0.8080 mL 2.0199 mL
80 mM 0.0606 mL 0.3030 mL 0.6060 mL 1.5149 mL
100 mM 0.0485 mL 0.2424 mL 0.4848 mL 1.2119 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ibuprofen
Cat. No.:
HY-78131
Quantity:
MCE Japan Authorized Agent: